FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999696085> ?p ?o ?g. }

• W2999696085 abstract "Abstract Background PredictSURE IBD™ is a CE-marked whole blood-based biomarker test that predicts long-term clinical outcomes in inflammatory bowel disease (Crohn’s disease, CD and ulcerative colitis, UC). PredictSURE IBD™ uses a 17-gene qPCR-based classifier to stratify patients into two prognostic subgroups, high and low risk. High-risk patients experience significantly more aggressive disease than low-risk patients, with the need for earlier and more frequent treatment escalation over time. Early stratification could enable personalised treatment strategies, such as ‘top-down’ use of biologics in high-risk patients. Our objective was to examine the cost-effectiveness of PredictSURE IBD™ in guiding the use of early biologic therapy in newly diagnosed CD patients in the UK. Methods A decision tree leading into a Markov state-transition model was constructed in MS Excel to compare two treatment approaches: (1) standard of care therapy following established UK clinical guidelines, consisting of sequences of immunomodulator followed by biologic upon relapse (‘step-up’ treatment), (2) targeted therapy guided by PredictSURE IBD™, whereby patients identified as high-risk receive sequences of anti-TNF biologic treatment followed by other biologic classes upon relapse (‘top-down’ treatment), Figure 1. Parameters were informed by patient data from PredictSURE IBD™ clinical studies and the literature. Results Top-down treatment guided by PredictSURE IBD™ resulted in an incremental cost-effectiveness ratio (ICER) of £7,179 per quality-adjusted life-year (QALY), with £1,852 incremental costs and 0.258 incremental QALYs vs. standard of care generated over a 15-year time horizon. Additional costs relating to earlier biologic use were offset by reductions in the costs of flares, hospitalisations and surgery. Incremental QALYs were driven by increased time spent in remission and improved quality of life from reduced flares and surgery. The model was most sensitive to the time horizon, rates of mucosal healing on top-down vs. step-up therapy, the costs of hospitalisation and the costs and quality of life in the severe disease health state. Conclusion Modelling shows that upfront use of biologic guided by PredictSURE IBD™ could substantially improve clinical outcomes for high-risk patients by increasing remission rates and reducing flares, surgery and treatment escalations. The ICER for PredictSURE IBD™ was well below the £20–£30k/QALY threshold used by the UK National Institute for Health and Care Excellence (NICE). Top-down treatment guided by PredictSURE IBD™ would not only represent a treatment paradigm shift for CD patients but would also be a highly cost-effective use of resources in the UK National Health Service." @default.
• W2999696085 created "2020-01-23" @default.
• W2999696085 creator A5004026303 @default.
• W2999696085 creator A5026620118 @default.
• W2999696085 creator A5050231754 @default.
• W2999696085 creator A5063849382 @default.
• W2999696085 creator A5072528165 @default.
• W2999696085 creator A5087459676 @default.
• W2999696085 date "2020-01-01" @default.
• W2999696085 modified "2023-09-23" @default.
• W2999696085 title "P195 Cost-effectiveness of a 17-gene classifier to guide initial treatment choice in Crohn’s disease in the UK" @default.
• W2999696085 doi "https://doi.org/10.1093/ecco-jcc/jjz203.324" @default.
• W2999696085 hasPublicationYear "2020" @default.
• W2999696085 type Work @default.
• W2999696085 sameAs 2999696085 @default.
• W2999696085 citedByCount "0" @default.
• W2999696085 crossrefType "journal-article" @default.
• W2999696085 hasAuthorship W2999696085A5004026303 @default.
• W2999696085 hasAuthorship W2999696085A5026620118 @default.
• W2999696085 hasAuthorship W2999696085A5050231754 @default.
• W2999696085 hasAuthorship W2999696085A5063849382 @default.
• W2999696085 hasAuthorship W2999696085A5072528165 @default.
• W2999696085 hasAuthorship W2999696085A5087459676 @default.
• W2999696085 hasBestOaLocation W29996960851 @default.
• W2999696085 hasConcept C126322002 @default.
• W2999696085 hasConcept C143998085 @default.
• W2999696085 hasConcept C2778260677 @default.
• W2999696085 hasConcept C2779134260 @default.
• W2999696085 hasConcept C2779280984 @default.
• W2999696085 hasConcept C2780479503 @default.
• W2999696085 hasConcept C71924100 @default.
• W2999696085 hasConceptScore W2999696085C126322002 @default.
• W2999696085 hasConceptScore W2999696085C143998085 @default.
• W2999696085 hasConceptScore W2999696085C2778260677 @default.
• W2999696085 hasConceptScore W2999696085C2779134260 @default.
• W2999696085 hasConceptScore W2999696085C2779280984 @default.
• W2999696085 hasConceptScore W2999696085C2780479503 @default.
• W2999696085 hasConceptScore W2999696085C71924100 @default.
• W2999696085 hasLocation W29996960851 @default.
• W2999696085 hasOpenAccess W2999696085 @default.
• W2999696085 hasPrimaryLocation W29996960851 @default.
• W2999696085 hasRelatedWork W1306813 @default.
• W2999696085 hasRelatedWork W1463911 @default.
• W2999696085 hasRelatedWork W1679810 @default.
• W2999696085 hasRelatedWork W3788956 @default.
• W2999696085 hasRelatedWork W5541502 @default.
• W2999696085 hasRelatedWork W5813897 @default.
• W2999696085 hasRelatedWork W6061786 @default.
• W2999696085 hasRelatedWork W6680660 @default.
• W2999696085 hasRelatedWork W7568419 @default.
• W2999696085 hasRelatedWork W7655147 @default.
• W2999696085 isParatext "false" @default.
• W2999696085 isRetracted "false" @default.
• W2999696085 magId "2999696085" @default.
• W2999696085 workType "article" @default.